Publications

Posters and Presentations

6/15/2024

First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of the First-in-Class TRPM3 Antagonist BHV-2100 in Development for Migraine and Pain

5/29/2024

Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator: Results from Phase 1 Single and Multiple Ascending Dose Studies

04/14/2024

Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features

04/16/2024

Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults

04/16/2024

Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults

04/17/2024

Characterization of BHV-7000: A Novel Kv7/2/7.3 Activator for the Treatment of Seizures

04/17/2024

Determinants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review

12/01/2023

Determinants of Health-Related Quality of Life of Patients With Focal Epilepsy: A Systematic Literature Review

12/01/2023

Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Seizures

12/01/2023

Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults

12/01/2023

Functional Impairments in Patients With KCNQ2-DEE: Associations Among Key Clinical Features

12/01/2023

A First in Human Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults

09/02/2023

Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy

03/13/2023

Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy

12/03/2022

Effects of retigabine and the novel M-current activator BHV-7000 on epilepsy-associated KCNQ2 variants

09/13/2023

Characterization of the Functional Efficacy of KB-1754, a Novel Kv7 Activator, on Smooth Muscle Contractility

5/29/2024

Two Randomized, Double-Blind, Placebo-Controlled Trials of Troriluzole, A Novel Glutamate Modulating Agent, in Obsessive-Compulsive Disorder

04/14/2024

Population Pharmacokinetic Modeling of Riluzole After Administration of a Next Generation Prodrug Troriluzole

04/14/2024

Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects

04/15/2024

Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders

04/15/2024

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects

04/15/2024

No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole

04/16/2024

Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia

04/16/2024

Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxias

04/16/2024

Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia

04/17/2024

Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia

9/12/2023

Understanding the Spectrum of SCA1, SCA2, SCA3 & SCA6 through the Eyes of Patients

10/16/2023

Understanding the Spectrum of SCA1, SCA2, SCA3 & SCA6 through the Eyes of Patients

3/3/2024

Content Validity of the Friedreich’s Ataxia Rating Scale – Activities of Daily Living (FARS-ADL) for Use in Patients With Spinocerebellar Ataxia (SCA)

3/3/2024

Measurement Properties of the Friedreich’s Ataxia Rating Scale–Activities of Daily Living in Patients With Spinocerebellar Ataxia

3/3/2024

Automated Video-Based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects With Spinocerebellar Ataxia

3/4/2024

Understanding the Spectrum of SCA1, SCA2, SCA3 & SCA6 through the Eyes of Patients: Burden of Illness and Quality of Life

5/25/2023

Understanding the Spectrum of SCA1, SCA2, SCA3, and SCA6 Through the Eyes of Patients: Burden of Illness Perspectives.

6/1/2023

Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder

11/17/2022

Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder

6/15/2024

First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of the First-in-Class TRPM3 Antagonist BHV-2100 in Development for Migraine and Pain

04/15/2024

BHV-2100, A First-In-Class TRPM3 Antagonist for the Treatment of Pain

09/07/2023

BHV-2100, a First-in-Class TRPM3 Antagonist for the Treatment of Neuropathic Pain

04/14/2024

The Phase 3 RESILIENT Study: Taldefgrobep Alfa in Spinal Muscular Atrophy

10/14/2023

10/14/2023

Taldefgrobep Alfa Reduces Fat and Increases Muscle in an Obese Mouse Model

Correlation Between Reduction in Total Body Weight and Change in Waist Circumference

07/01/2023

Taldefgrobep Alfa: The Phase 3 RESILIENT Study in Spinal Muscular Atrophy

06/20/2023

Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy

03/20/2023

Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy

12/09/2023

Expansion, Persistence, and Characteristics of Autologous, BHV-1100 ARMored Memory-Like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+, Multiple Myeloma Patients

09/27/2023

Expansion, Persistence, and Characteristics of Autologous, BHV-1100 ARMored Memory-Like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+, Newly Diagnosed Multiple Myeloma Patients

04/14/2024

Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson's Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases

04/14/2024

Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson's Disease Progression in Untreated Patients Using Parkinson's Progression Markers Initiative Data

04/17/2024

Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson's Disease Progression Using Parkinson's Progression Markers Initiative Natural History Data

3/8/2024

Association of Anti-Inflammatory Therapy Use With the Incidence of Parkinson’s Disease: A Person-Time Analysis Among Patients With Autoimmune Diseases

3/8/2024

Weighting MDS-UPDRS motor items for optimal sensitivity to Parkinson’s Disease progression in untreated patients using Parkinson’s Progression Markers Initiative data

3/8/2024

Weighting MDS-UPDRS Part II items for optimal sensitivity to Parkinson’s disease progression using Parkinson’s Progression Markers Initiative natural history data

3/19/2024

BHV-1400 Targets the Non-Immunosuppressive, Selective Depletion of Circulating Galactose-Deficient IGA1 in IGA Nephropathy

04/18/2024

Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates